Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. (Nasdaq: DYN) is a clinical-stage biopharmaceutical company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The DYN news feed highlights company announcements related to its neuromuscular pipeline, corporate strategy and financial position.
News coverage for Dyne commonly includes updates on its lead clinical programs, zeleciment rostudirsen (z-rostudirsen, DYNE-251) for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping and zeleciment basivarsen (z-basivarsen, DYNE-101) for myotonic dystrophy type 1 (DM1). Investors can follow topline and long-term data readouts from the Phase 1/2 DELIVER and ACHIEVE trials, including biomarker results, functional endpoints, safety and tolerability findings, and regulatory milestones such as Breakthrough Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug designations.
The DYN news stream also features information on Dyne’s preclinical programs in facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease, presentations at scientific and investor conferences, and corporate developments such as public offerings of common stock, loan agreements and board appointments. Periodic financial results and business updates provide additional context on cash runway, planned regulatory submissions and the company’s preparation for potential commercialization of its neuromuscular therapies.
By monitoring this page, readers can review Dyne’s press releases on clinical progress, regulatory interactions, financing transactions and conference presentations in one place. This historical record of company communications helps investors, analysts and other stakeholders understand how Dyne’s FORCE platform, pipeline and corporate activities are evolving over time.
Dyne Therapeutics (Nasdaq: DYN) will present three posters at the AMCP 2026 Annual Conference in Nashville, April 13-16, 2026, covering Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).
Presentations include DELIVER and ACHIEVE trial data, a DM1 health insurance literacy study developed with Myotonic Dystrophy Foundation, and a payer-focused symposium on April 14, 12:00–1:30 p.m. CT. Dyne said these activities aim to inform managed care access decisions ahead of potential DMD and DM1 launches.
Dyne Therapeutics (Nasdaq: DYN) initiated the Phase 3 HARMONIA trial of z-basivarsen (DYNE-101) in myotonic dystrophy type 1 (DM1).
The global, randomized, double-blind trial will enroll approximately 150 participants (age 16+) randomized 1:1 to 6.8 mg/kg IV every eight weeks or placebo for a 48-week treatment period. The primary endpoint is change in the five times sit to stand (5xSTS) at week 49. Secondary and exploratory measures cover muscle function, CNS domains, and patient- and clinician-reported outcomes. The protocol is aligned with the FDA and is intended to support conversion to traditional U.S. approval and ex-U.S. marketing applications.
Dyne Therapeutics (Nasdaq: DYN) reported new 24-month cardiopulmonary analyses from the Phase 1/2 DELIVER trial of z-rostudirsen (DYNE-251) in exon 51 skip–amenable Duchenne muscular dystrophy. Improvements were seen versus expected natural-history declines in FVC%p, circumferential strain, and left ventricular ejection fraction at 24 months. Safety data from 86 participants followed up to 36 months showed mostly mild-to-moderate related TEAEs, chiefly pyrexia and headache, and no related serious TEAEs in the reported cohort. Findings were presented as a late-breaking poster at the 2026 MDA Clinical & Scientific Conference.
Dyne Therapeutics (Nasdaq: DYN) reported Q4 and full-year 2025 results and program updates on March 2, 2026. Key clinical milestones include positive registrational REC topline results for z-rostudirsen (dystrophin 5.46% of normal at six months) and planned BLA submission in Q2 2026.
Cash totaled $1.1 billion at year-end, with the company reaffirming runway into Q1 2028. Enrollment and Phase 3 plans for z-basivarsen (DM1) and additional DMD exon programs are underway.
Dyne Therapeutics (Nasdaq: DYN) said management will participate in several investor conferences in March 2026, including TD Cowen (fireside chat Mar 4), Jefferies Biotech on the Beach (meetings Mar 10–11) and Stifel Virtual CNS Forum (fireside chat Mar 17).
Live webcasts of each fireside chat will be available on Dyne's Investors & Media site and replays accessible for 90 days.
Dyne Therapeutics (Nasdaq: DYN) will present five abstracts, including three oral talks, at the 2026 MDA Clinical & Scientific Conference March 8-11, 2026, covering Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and Pompe disease.
Highlights include late-breaking DELIVER cardiopulmonary function data for z-rostudirsen (DYNE-251), a Phase 3 design for z-basivarsen (DYNE-101) in DM1, and preclinical DYNE-401 Pompe data; posters and slides will be posted on the company website in sync with the conference.
Dyne Therapeutics (Nasdaq: DYN) announced that Japan's Ministry of Health, Labour and Welfare granted Orphan Drug designation to zeleciment basivarsen (z-basivarsen) for the treatment of myotonic dystrophy type 1 (DM1) on January 20, 2026. Z-basivarsen is in a Phase 1/2 ACHIEVE trial and has shown sustained functional improvement in myotonia, muscle strength and function with a favorable safety profile. Dyne expects to complete enrollment in the ACHIEVE Registrational Expansion Cohort in early Q2 2026. The designation in Japan complements prior U.S. and European designations and may provide development subsidies and up to 10 years of market exclusivity if approved.
Dyne Therapeutics (Nasdaq: DYN) announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET).
A live webcast will be available in the Investors & Media section of Dyne’s website and a replay will be accessible for 30 days.
Dyne Therapeutics (Nasdaq: DYN) appointed Vikram Karnani to its Board of Directors on December 23, 2025. Mr. Karnani is CEO of Collegium Pharmaceutical since November 2024 and previously led commercial and rare disease operations at Amgen and Horizon Therapeutics.
The company said his commercial and launch experience will support Dyne’s advance toward commercialization and a potential first launch in Q1 2027. Background details include leadership roles tied to a $28 billion acquisition integration and helping grow a Horizon rare disease business from $500M to over $3B in revenue.
Dyne Therapeutics (Nasdaq: DYN) closed an upsized underwritten public offering on Dec 11, 2025, selling 21,827,549 shares of common stock at a public offering price of $18.44 per share.
The total gross proceeds to Dyne were approximately $402.5 million before underwriting discounts, commissions and offering expenses. The offering included 2,847,071 shares issued upon full exercise of the underwriters' option to purchase additional shares. All shares were sold by Dyne under a shelf registration on Form S-3 that became effective March 5, 2024.